BB-501

**BB-501** is an investigational ddRNAi (DNA-directed RNA interference) therapeutic developed by Benitec Biopharma as a follow-on to BB-401, designed to silence **EGFR** (epidermal growth factor receptor) expression for the treatment of **head and neck cancer**. It functions by delivering a DNA plasmid that expresses short hairpin RNAs to induce potent, durable gene knockdown of EGFR, a key driver of tumor growth in squamous cell carcinomas of the head and neck. Preclinical studies in mouse xenograft models have demonstrated anti-tumor efficacy, and clinical data from the related BB-401 program are informing its development pathway, with current global R&D status listed as **Pending**.[1][3][5][8][16]